XML 25 R7.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($)
shares in Millions, $ in Millions
Total
Common Stock
Treasury Stock
Common Stock Including Additional Paid in Capital
Retained Earnings
Accumulated Other Comprehensive Income (Loss)
CVS Health Shareholders' Equity
Noncontrolling Interest
Shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2017   1,712 (698) [1]          
Balance at beginning of period at Dec. 31, 2017 $ 37,695   $ (37,796) [1] $ 32,096 [2] $ 43,556 $ (165) $ 37,691 $ 4
Shareholders' Equity [Roll Forward]                
Net income (loss) 998       998   998  
Other comprehensive income (loss) 344         344 344  
Stock option activity, stock awards and other (in shares)   2            
Stock option activity, stock awards and other 112     112 [2]     112  
Purchase of treasury shares, net of ESPP issuances 49   $ 49 [1]       49  
Common stock dividends (508)       (508)   (508)  
Shares outstanding, balance at end of period (in shares) at Mar. 31, 2018   1,714 (698) [1]          
Balance at end of period at Mar. 31, 2018 38,677   $ (37,747) [1] 32,208 [2] 44,040 172 38,673 4
Shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2017   1,712 (698) [1]          
Balance at beginning of period at Dec. 31, 2017 37,695   $ (37,796) [1] 32,096 [2] 43,556 (165) 37,691 4
Shareholders' Equity [Roll Forward]                
Other comprehensive income (loss) 313         313    
Shares outstanding, balance at end of period (in shares) at Jun. 30, 2018   1,716 (699) [1]          
Balance at end of period at Jun. 30, 2018 35,611   $ (37,780) [1] 32,281 [2] 40,965 141 35,607 4
Shares outstanding, balance at beginning of period (in shares) at Mar. 31, 2018   1,714 (698) [1]          
Balance at beginning of period at Mar. 31, 2018 38,677   $ (37,747) [1] 32,208 [2] 44,040 172 38,673 4
Shareholders' Equity [Roll Forward]                
Net income (loss) (2,563)       (2,563)   (2,563)  
Other comprehensive income (loss) (31)         (31) (31)  
Stock option activity, stock awards and other (in shares)   2            
Stock option activity, stock awards and other 73     73 [2]     73  
Purchase of treasury shares, net of ESPP issuances (in shares) [1]     (1)          
Purchase of treasury shares, net of ESPP issuances (33)   $ (33) [1]       (33)  
Common stock dividends (512)       (512)   (512)  
Shares outstanding, balance at end of period (in shares) at Jun. 30, 2018   1,716 (699) [1]          
Balance at end of period at Jun. 30, 2018 35,611   $ (37,780) [1] 32,281 [2] 40,965 141 35,607 4
Shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2018   1,720 (425) [3]          
Balance at beginning of period at Dec. 31, 2018 58,543   $ (28,228) [3] 45,440 [4] 40,911 102 58,225 318
Shareholders' Equity [Roll Forward]                
Net income (loss) 1,427       1,421   1,421 6
Other comprehensive income (loss) 331         331 331  
Stock option activity, stock awards and other (in shares)   2            
Stock option activity, stock awards and other 175     175 [4]     175  
Purchase of treasury shares, net of ESPP issuances (in shares) [3]     1          
Purchase of treasury shares, net of ESPP issuances 7   $ 7 [3]       7  
Common stock dividends (651)       (651)   (651)  
Other decreases in noncontrolling interests (4)             (4)
Shares outstanding, balance at end of period (in shares) at Mar. 31, 2019   1,722 (424) [3]          
Balance at end of period at Mar. 31, 2019 60,006   $ (28,221) [3] 45,615 [4] 41,859 433 59,686 320
Shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2018   1,720 (425) [3]          
Balance at beginning of period at Dec. 31, 2018 58,543   $ (28,228) [3] 45,440 [4] 40,911 102 58,225 318
Shareholders' Equity [Roll Forward]                
Other comprehensive income (loss) 582         582    
Shares outstanding, balance at end of period (in shares) at Jun. 30, 2019   1,724 (425) [3]          
Balance at end of period at Jun. 30, 2019 61,599   $ (28,257) [3] 45,719 [4] 43,136 684 61,282 317
Shares outstanding, balance at beginning of period (in shares) at Mar. 31, 2019   1,722 (424) [3]          
Balance at beginning of period at Mar. 31, 2019 60,006   $ (28,221) [3] 45,615 [4] 41,859 433 59,686 320
Shareholders' Equity [Roll Forward]                
Net income (loss) 1,931       1,936   1,936 (5)
Other comprehensive income (loss) 251         251 251  
Stock option activity, stock awards and other (in shares)   2            
Stock option activity, stock awards and other 104     104 [4]     104  
Purchase of treasury shares, net of ESPP issuances (in shares) [3]     (1)          
Purchase of treasury shares, net of ESPP issuances (36)   $ (36) [3]       (36)  
Common stock dividends (659)       (659)   (659)  
Other decreases in noncontrolling interests 2             2
Shares outstanding, balance at end of period (in shares) at Jun. 30, 2019   1,724 (425) [3]          
Balance at end of period at Jun. 30, 2019 $ 61,599   $ (28,257) [3] $ 45,719 [4] $ 43,136 $ 684 $ 61,282 $ 317
[1]
Treasury shares include 1 million shares held in trust as of June 30, 2018, March 31, 2018 and December 31, 2017. Treasury stock includes $31 million related to shares held in trust as of June 30, 2018, March 31, 2018 and December 31, 2017.
[2]
Common stock and capital surplus includes the par value of common stock of $17 million as of June 30, 2018, March 31, 2018 and December 31, 2017.
[3]
Treasury shares include 1 million shares held in trust as of June 30, 2019, March 31, 2019 and December 31, 2018. Treasury stock includes $29 million related to shares held in trust as of June 30, 2019, March 31, 2019 and December 31, 2018.
[4]
Common stock and capital surplus includes the par value of common stock of $17 million as of June 30, 2019, March 31, 2019 and December 31, 2018.